GWM
LGND icon

Gilpin Wealth Management’s Ligand Pharmaceuticals LGND Stock Holding History

Gilpin Wealth Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$938 Hold
3
– – ﹤0.01% 701
2026
Q2 		$949 Hold
3
– – ﹤0.01% 516
2026
Q1 		$599 Buy
3
+1
+50% +$198 ﹤0.01% 564
2025
Q4 		$379 Buy
+2
New +$384 ﹤0.01% 494

Other funds holding LGND

CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
MNBTD
Moody National Bank Trust Division Galveston, Texas $1.21B AUM 28.25% 1-Year Est. Return
ACM
Argent Capital Management St Louis, Missouri $3.14B AUM 31.36% 1-Year Est. Return
VAG
VisionPoint Advisory Group Dallas, Texas $636M AUM 21.4% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Gilpin Wealth Management's LGND Position: Q3 2026 in Review

Gilpin Wealth Management held its Ligand Pharmaceuticals (LGND) position steady in Q3 2026 at 3 shares worth $938. The position accounts for ﹤0.01% of the portfolio, ranked #701.

Gilpin Wealth Management first reported a position in LGND in Q4 2025 and has held it in 4 quarters since. The position peaked at $949 in Q2 2026. 14 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

  • Gilpin Wealth Management held 3 shares of Ligand Pharmaceuticals worth $938 as of Q3 2026.
  • Gilpin Wealth Management left its Ligand Pharmaceuticals share count unchanged in Q3 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of Gilpin Wealth Management's portfolio in Q3 2026, its #701 holding.
  • Gilpin Wealth Management first reported a position in Ligand Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • Gilpin Wealth Management's Ligand Pharmaceuticals position peaked at $949 in Q2 2026.
  • 14 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on Gilpin Wealth Management's 13F filing for Q3 2026, filed 9 Oct 2026.